Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1088 - Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 - REGOLD

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

thomas Aparicio

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

T. Aparicio1, A. Darut Jouve2, F. Khemissa3, C. Montérymard4, P. Artru5, L. Cany6, O. Romano7, B. Valenza8, C. Le Foll9, C. Delbaldo10, C. Falandry11, M. Duluc12, Y. Rinaldi13, J.L. Legoux14, M. Ben Abdelghani15, E. Assenat16, M. Dhooge17, D. Smith18, G. Des Guetz19, C. Lepage20

Author affiliations

  • 1 Gastroenterology, CHU Saint Louis, 75010 - Paris/FR
  • 2 Oncology, Institut of Cancerology of Burgundy, 21000 - Dijon/FR
  • 3 Department Of Hepatology Gastro Enterology, CH Perpignan, Hospital Saint Jean, 66046 - Perpignan/FR
  • 4 Biostatistic, FFCD, 21079 - Dijon/FR
  • 5 Oncology, Hospital Jean Mermoz, 69373 - Lyon/FR
  • 6 Department Of Radiotherapy And Oncology, Polyclinique Francheville, 24004 - PERIGUEUX/FR
  • 7 Oncology, Centre GALILEE, 59045 - Lille/FR
  • 8 Oncology, CHI of Fréjus – Saint-Raphaël, 83608 - Fréjus/FR
  • 9 Centre De Traitement Du Cancer - Site De Marne La Vallée, Grand Hôpital de l'Est Francilien, 77600 - JOSSIGNY/FR
  • 10 Oncology, Hôpital des Diaconesses - Croix Saint Simon, 75000 - PARIS/FR
  • 11 Oncology, CH Lyon Sud, 69495 - Pierre Bénite/FR
  • 12 Department Of Hepato Gastroenterology And Medical Oncology, CHU La Timone Adults, 13385 - Marseille/FR
  • 13 Department Of Hepato Gastroenterology, Hospital European Marseille, 13331 - MARSEILLE/FR
  • 14 Hepato-gastroenterolgy And Digestive Oncology, C.H.R. Orleans - La Source, 45100 - Orleans/FR
  • 15 Department Of Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 16 Digestive Oncology, CHU Saint Eloi, 34295 - Montpellier/FR
  • 17 Department Of Hepato Gastroenterology, Hospital Cochin, 75679 - PARIS/FR
  • 18 Digestive Oncology, CHU of Bordeaux, 33000 - Bordeaux/FR
  • 19 Department Of Oncology, CHU Dupuytren, 87042 - Limoges/FR
  • 20 Department Of Hepato Gastroenterology And Digestive Oncology, University hospital Dijon ; EPICAD INSERM LNC-UMR 1231, University of Burgundy and Franche Comté, 21079 - Dijon/FR
More

Resources

Abstract 1088

Background

Regorafenib (REG) significantly increases overall survival (OS) in previously treated mCRC pts. However, no prospective trial specific to elderly population including geriatric parameter evaluation has evaluated the safety and efficacy of REG in its registered indication.

Methods

Multicenter one-arm phase II that enrolled pts ≥70 years, ECOG performance status ≤1, with mCRC after failure of fluoropyrimidine-based chemotherapy, anti-VEGF and anti-EGFR treatment. Primary endpoint was tumor control rate 2 months after initiation of REG administered at 160mg/day (3weeks on/1 week off).

Results

43 pts were enrolled from January 2016 to April 2017, median age 77 (range 70 – 91), ECOG 0: 37.2%, ECOG 1: 60.5%, altered activities of daily living (ADL) in 37.5%. Median time from diagnosis of metastases to enrolment: 27.7 months, median number of previous lines: 3. At the time of analysis, the median follow-up was 13.3 months and 62.8% pts had died. One patient never started treatment. The median duration of REG treatment was 45.0 days [5 to 440]. 8 patients were not evaluable for the primary endpoint. Tumor control rate at 2 months in the 35 evaluable pts was 31.4% [18.7% – 46.6%]. Among the 11 pts with tumor control, 9 (81.8%) were < 80 yrs. In the 42 treated pts, median progression free survival (PFS) and OS were 2.2 [1.9-3.3] and 7.5 [5.5-14.6] months, respectively. Modification of the initial dose was performed in 54.3% of the 116 cycles delivered. A grade 3-4 adverse event was observed in 37 (88.1%) pts notably: asthenia (45.2%), hand foot syndrome (21.4%), arterial hypertension (21.4%), and diarrhea (7.1%). Treatment was stopped for toxicity without progression in 12 (28.6%) pts. Among them, 10 (83.3%) pts were ECOG 1, 6 (50%) were over 80 years and 6 (50%) had abnormal baseline ADL. No toxic death was observed.

Conclusions

Treatment with REG in heavily pretreated elderly pts gives a tumor control at 2 months in around 30% of pts. The median PFS and OS are comparable to those observed in the pivotal study. With caution due to small number, drop-out rate for treatment toxicity seems higher in pts with ECOG 1, age over 80 yrs and abnormal ADL.

Clinical trial identification

EudraCT: 2015-002086-29.

Legal entity responsible for the study

Fédération Francophone de Cancérologie Digestive.

Funding

Bayer.

Editorial Acknowledgement

Disclosure

T. Aparicio: Consulting or advisory role: Pierre Fabre, Ipsen, Halio DX, Bristol-Myers Squibb; Travel, accommodations, expenses: Ipsen, Novartis, Ipsen, Roche, Hospira; Honoraria: Pfizer, Roche, Sanofi, Léo Pharma, Amgen, Bristol-Myers Squibb, Servier; Research funding: Bayer. A. Darut Jouve: Travel, accommodations, expenses: Novartis, Bayer. F. Khemissa: Travel, accommodations, expenses: Ipsen, Roche, Sanofi, Bayer; Honoraria: Sanofi, Roche, Bayer; Speakers' bureau: Sanofi, Roche. P. Artru: Consulting or advisory role: Roche, Merck; Travel, accommodations, expenses: Roche, Merck, Bayer; Honoraria: Roche, Amgen, Bayer, Servier, Lilly, Merck; Speakers' bureau: Roche, Merck, Servier. L. Cany: Travel, accommodations, expenses: Novartis. O. Romano: Consulting or advisory role: Roche, Sanofi, Pierre Fabre; Travel, accommodations, expenses: Novartis; Honoraria: Roche, Sanofi, Pierre Fabre; Research funding: Sanofi. C. Falandry: Consulting or advisory role: Pfizer, AstraZeneca, Novartis, Teva, Pierre Fabre, Roche; travel, accommodations, expenses: AstraZeneca, Roche, Pfizer; Honoraria: Pfizer, AstraZeneca, Novartis. M. Duluc: ravel, accommodations, expenses: Ipsen. J.L. Legoux: Consulting or advisory role: Lilly, Novartis; Travel, accommodations, expenses: Merck Serono, Lilly, Ipsen, Novartis; Honoraria: Novartis Research funding: Sanofi/Regeneron. M. Ben Abdelghani: Consulting or advisory role: Amgen, Sanofi, Merck Serono, Bayer, Ipsen, Novartis/Pfizer Travel, accommodations, expenses: Roche, Amgen, Novartis/Pfizer, Ipsen, Bayer, Sandoz, Sanofi. E. Assenat: Consulting or advisory role: Ipsen, Sanofi; Travel, accommodations, expenses: Bayer, Ipsen; Honoraria: Bayer, Sirtex Medical. M. Dhooge: Travel, accommodations, expenses: Norgine SAS. C. Lepage: Consulting or advisory role: Advanced Accelerator Applications; Travel, accommodations, expenses: Amgen, Novartis, Ipsen, Bayer; Honoraria: Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings